GT Medical Technologies Completes $100M Series E for GammaTile Brain Tumor Therapy
Summary
GT Medical Technologies has closed an oversubscribed $100 million Series E equity financing led by Viking Global Investors with participation from MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. The company develops GammaTile, an FDA-cleared bioresorbable radiotherapy implant placed at the time of brain tumor removal surgery. The ROADS randomized controlled trial demonstrated that GammaTile reduced tumor recurrence risk by 93% and death risk by 41% at 12 months compared to standard of care. Funds will accelerate commercial expansion and support the BRIDGES RCT in glioblastoma patients.
Why it matters
This financing represents one of the largest Series E rounds in neuro-oncology device history and validates GammaTile's clinical value proposition with strong randomized trial data. The oversubscribed nature of the round and Viking Global's participation signal crossover investor interest in neurotechnology with hard clinical evidence. For patients with operable brain tumors, this funding accelerates access to a therapy that addresses a significant unmet need where standard treatments leave dangerous gaps between surgery and radiation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial